1. I am bullish on Glenmark Pharmaceuticals as a company at the current valuations as stock market meltdown has provided an opportunity for one to earn quality returns. Glenmark Pharmaceuticals has 13 products in the US market and 36 ANDAs pending approval. As a net result of these efforts one can see it achieveing continous growth in the US market. One can buy this stock with a target of Rs 390 with in a time span of 12 months. One can buy this stock now to benefit from lower stock price prevailing and this is one of the best pharma sector stock at current price levels.
2. Moreover company is already on the path of takeovers with seven pharmaceutical brands in Poland from Iceland-based Actavis and its affiliate Biovena under its belt. The acquisitions help the company to get a foot hold in Poland and thus new avenues are opened for the company in new geographical areas. Moreover it will have a sale of $15 million from the seven brands for 2008-09 with a 20 per cent growth in 2009-10. Moreover it is expected to have a EPS of Rs 52 for FY09.
2. Moreover company is already on the path of takeovers with seven pharmaceutical brands in Poland from Iceland-based Actavis and its affiliate Biovena under its belt. The acquisitions help the company to get a foot hold in Poland and thus new avenues are opened for the company in new geographical areas. Moreover it will have a sale of $15 million from the seven brands for 2008-09 with a 20 per cent growth in 2009-10. Moreover it is expected to have a EPS of Rs 52 for FY09.
